Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
US-2024246901-A1 · Jul 25, 2024 · US
US9650355B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9650355-B2 |
| Application number | US-201414760400-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 28, 2014 |
| Priority date | Jan 31, 2013 |
| Publication date | May 16, 2017 |
| Grant date | May 16, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to a novel method for preparing an arylnaphthalene lignan compound. In synthesis of arylnaphthalene lignan compounds and derivatives according to the present disclosure, a naphthalene backbone may be constructed first and an aryl group may be introduced at the final stage. Through this, various kinds of derivatives that could not be prepared from the existing methods can be synthesized effectively. Further, the synthesis method according to the present disclosure is appropriate for large-scale production.
Opening claim text (preview).
The invention claimed is: 1. A method for preparing a precursor of an arylnaphthalene lignan compound using Scheme A: wherein each of A and B is independently C1-C8 alkyl or C2-C9 alkylether or A and B are linked via methylene to form a heterocycle; X is —O, —NR1 or —CH2—; n is 1 or 2; R1 is C1-C8 alkyl or C7-C14 arylalkyl; and M is lithium, potassium or sodium. 2. The method according to claim 1 , wherein the arylnaphthalene lignan compound has a structure of Chemical Formula 6 or 9: wherein Y is hydroxyl, sulfonate, wherein Ar is R 2 is hydrogen, C 1 -C 8 alkyl, C 1 -C 4 alkyloxy, C 1 -C 4 alkylether, C 1 -C 4 alkylthiooxy, vinyl, C 3 C 8 alkylvinyl, hydroxyl, nitro (—NO 2 ), fluoro, chloro, cyano, formyl (—CHO), C 2 -C 12 acyl, C 1 -C 5 alkylester or C 7 -C 10 arylester; R 3 is C 1 -C 10 alkyl, C 6 -C 12 aryl, C 7 -C 10 alkylaryl, C 2 -C 10 arylalkyl, C 1 -C 4 alkylether, C 1 -C 5 alkylester or C 2 -C 12 acyl; R 4 is hydrogen, C 1 -C 6 alkyl, C 7 -C 12 cyclohexylalkyl, C 7 -C 12 arylalkyl, C 2 -C 6 alkylether, C 2 -C 6 alkylthioether, C 2 -C 6 alkylcyano, C 1 -C 4 alkylalcohol or R 5 is independently hydrogen, C 1 -C 6 alkyl, C 7 -C 12 cyclohexylalkyl, C 7 -C 12 arylalkyl, C 2 -C 6 alkylether, C 2 -C 6 alkylthioether, C 2 -C 6 alkylcyano, C 1 -C 4 alkylalcohol or R 6 is hydrogen, C 1 -C 6 alkyl, C 7 -C 10 ) alkylaryl, C 1 -C 4 alkylether, C 1 -C 4 alkylthioether, fluoro or chloro; o is an integer from 1 to 5; and p is an integer from 0 to 2, and Z is O—R 7 , or glycosyl wherein R 7 is hydrogen, C 1 -C 8 alkyl, C 2 -C 9 alkylether, C 1 -C 5 alkylester, C 7 -C 10 arylester or R 8 is C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, nitro (—NO 2 ), cyano (—CN), fluoro, chloro, bromo, iodo or hydrogen; q is an integer from 0 to 5; r is an integer from 1 to 4; R 9 is C 1 -C 8 alkyl or hydrogen; s is an integer from 1 to 5; and the glycosyl group is 4-Oβ-D-galactopyranosyl, 4-O-α-L-arabinosyl, 4O-β-D-glucopyranosyl, 4-O-β-D-xylosyl, 6′-O-methyl-4-O-β-D-glucopyranosyl, 6′-O-methyl-4-O-β-D-galactopyranosyl, 4-O-β-D-fucopyranosyl, 6′-O-benzyl-4O-β-D-glucopyranosyl or 6′-0-benzyl-4-O-β-D-galactopyranosyl. 3. The method according to claim 1 , wherein the arylnaphthalene lignan compound is 9-(benzo[d][1,3]dioxol-5-yl)-4,6,7-trimethoxynaphtho[2,3-c]furan-1(3H)-one (justicidin A), t-butyl 9-hydroxy-6,7-dimethoxy-1-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 9-(t-butoxycarbonyloxy)-6,7-dimethoxy-3-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl trifluoromethanesulfonate, 9-(benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-1-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl t-butylcarbonate, 9-(benzo[d][1,3]dioxol-5-yl)-4-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one (diphyllin), 9-(3,4-dimethoxyphenyl)-4,6,7-trimethoxynaphtho[2,3-c]furan-1(3H)-one (cilinaphthalide B), t-butyl 9-(3,4-dimethoxyphenyl)-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 9-(3,4-dimethoxyphenyl)-4-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one, 9-(3,5-dimethoxyphenyl)-4,6,7-trimethoxynaphtho[2,3-c]furan-1(3H)-one, t-butyl 9-(3,5-dimethoxyphenyl)-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 9-(3,5-dimethoxyphenyl)-4-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one, 4,6,7-trimethoxy-9-(4-methoxyphenyl)naphtho[2,3-c]furan-1(3H)-one, t-butyl 6,7-dimethoxy-9-(4-methoxyphenyl)-1-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 4-hydroxy-6,7-dimethoxy-9-(4-methoxyphenyl)naphtho[2,3-c]furan-1(3H)-one, 4,6,7-trimethoxy-9-phenylnaphtho[2,3-c]furan-1(3H)-one, t-butyl 6,7-dimethoxy-1oxo-9-phenyl-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 4-hydroxy-6,7-dimethoxy-9-phenylnaphtho[2,3-c]furan-1(3H)-one, 4,6,7-trimethoxy-9-(4-vinylphenyl)naphtho[2,3-c]furan-1(3H)-one, t-butyl 6,7-dimethoxy-1oxo-9-(4-vinylphenyl)-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 4-hydroxy-6,7-dimethoxy-9-(4-vinylphenyl)naphtho[2,3-c]furan-1(3H)-one, 9-(4-fluorophenyl)-4,6,7-trimethoxynaphtho[2,3-c]furan-1(3H)-one, t-butyl 9-(4-fluorophenyl)-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 9-(4-fluorophenyl)-4-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one, 4-(9-hydroxy-6,7-dimethoxy-3-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl)benzonitrile, t-butyl 9-(4-cyanophenyl)-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 4-(9-hydroxy-6,7-dimethoxy-3-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl)benzonitrile, 9-(4-acetylphenyl)-4,6,7-trimethoxynaphtho[2,3-c]furan-1(3H)-one, 9-(4-acetylphenyl)-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl t-butylcarbonate, 9-(4-acetylphenyl)-4-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one, 4,6,7-trimethoxy-9-(thiophen-3-yl)naphtho[2,3-c]furan-1(3H)-one, 4-hydroxy-6,7-dimethoxy-9-(thiophen-3-yl)naphtho[2,3-c]furan-1(3H)-one, 9-(furan-3-yl)-4,6,7-trimethoxynaphtho[2,3-c]furan-1(3H)-one, t-butyl 9-(furan-3-yl)-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl carbonate, 9-(furan-3-yl)-4-hydroxy-6,7-dimethoxynaphtho[2,3-c]furan-1(3H)-one, (E)-4,6,7-trimethoxy-9-styrylnaphtho[2,3-c]furan-1(3H)-one, (E)-4-hydroxy-6,7-dimethoxy-9-styrylnaphtho[2,3-c]furan-1(3H)-one, 5-(1,3-benzodioxol-5-yl)-9-methoxy-furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(8H)-one (justicidin F, taiwanin E methyl ether), t-butyl 9-hydroxy-1oxo-1,3-dihydronaphtho[2,3-d]-1,3-dioxol[2,3-c]furan-4-yl carbonate, 9-(t-butoxycarbonyloxy)-3-oxo-1,3-dihydronaphtho[2,3-d]-1,3-dioxol[2,3-c]furan-4-yl trifluoromethanesulfonate, 9-(benzo[d][1,3]dioxol-5-yl)-1-oxo-1,3-dihydronaphtho[2,3-d]-1,3-dioxol[2,3-c]furan-4-yl t-butylcarbonate, 5-(1,3-benzodioxol-5-yl)-9-hydro-furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(8H)-one (taiwanin E), 4-(benzo[d][1,3]dioxol-5-yl)-6,'7,9-trimethoxynaphtho[2,3-c]furan-1(3H)-one (justicidin C), 9-hydroxy-6,7-dimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl methanesulfonate, 6,7,9-trimethoxy-1oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl methanesulfonate or 9-benzo[1,3]dioxol-5-yl-4,6,7-trimethoxy-2-methyl-2,3-dihydro-benzo[f]isoindol-1-one. 4. The method according to claim 1 , wherein Scheme A comprises: Michael reaction; aldol reaction; and benzannulation. 5. The method according to claim 1 , wherein the base in Scheme A is one or more selected from a group consisting of lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, lithium t-butoxide, potassium t-butoxide, sodium t-butoxide, lithium diisopropylamide, s-butyllithium and t-butyllithium. 6. The method according to claim 1 , wherein, in Scheme A, the α,β-unsaturated carbonyl compound is used in an amount of 1.0-3.0 equivalents based on the compound of Chemical Formula 1. 7. A method of pr
directly linked by a ring-member-to-ring-member bond · CPC title
with one oxygen atom directly attached in position 1 or 3 · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Ortho-condensed systems · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.